CHICAGO TRUST Co NA Has $507,000 Stake in Edwards Lifesciences Co. (NYSE:EW)

CHICAGO TRUST Co NA lifted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,306 shares of the medical research company’s stock after buying an additional 381 shares during the period. CHICAGO TRUST Co NA’s holdings in Edwards Lifesciences were worth $507,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Edwards Lifesciences by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock valued at $3,992,709,000 after purchasing an additional 729,984 shares during the last quarter. Brown Advisory Inc. increased its stake in Edwards Lifesciences by 20.1% in the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock valued at $1,386,333,000 after buying an additional 3,048,274 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Edwards Lifesciences by 2.4% during the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock worth $1,283,098,000 after buying an additional 393,109 shares during the last quarter. Norges Bank bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $648,540,000. Finally, Sands Capital Management LLC raised its holdings in Edwards Lifesciences by 34.6% during the fourth quarter. Sands Capital Management LLC now owns 6,103,702 shares of the medical research company’s stock worth $465,407,000 after acquiring an additional 1,567,526 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.8 %

Edwards Lifesciences stock opened at $90.15 on Tuesday. The firm has a market cap of $54.32 billion, a price-to-earnings ratio of 38.86, a PEG ratio of 3.33 and a beta of 1.11. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The firm has a 50 day moving average price of $87.48 and a two-hundred day moving average price of $84.80.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. Equities analysts predict that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, CEO Bernard J. Zovighian bought 580 shares of the stock in a transaction on Monday, May 6th. The stock was acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $94.89, for a total transaction of $688,426.95. Following the transaction, the chief financial officer now directly owns 19,074 shares of the company’s stock, valued at approximately $1,809,931.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Bernard J. Zovighian purchased 580 shares of the business’s stock in a transaction on Monday, May 6th. The stock was purchased at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the acquisition, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The disclosure for this purchase can be found here. Insiders have sold 127,104 shares of company stock valued at $11,267,464 in the last ninety days. 1.27% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on EW. Royal Bank of Canada raised their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Morgan Stanley raised their price objective on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Wells Fargo & Company lifted their price objective on shares of Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Finally, Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.06.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.